Alison Bauerlein Sells 10,130 Shares of Sight Sciences, Inc. (NASDAQ:SGHT) Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CFO Alison Bauerlein sold 10,130 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $6.08, for a total transaction of $61,590.40. Following the completion of the sale, the chief financial officer now directly owns 392,555 shares of the company’s stock, valued at $2,386,734.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Sight Sciences Price Performance

Shares of SGHT stock opened at $5.81 on Friday. The firm has a fifty day moving average of $6.50 and a two-hundred day moving average of $6.23. The firm has a market cap of $289.08 million, a P/E ratio of -5.19 and a beta of 2.71. Sight Sciences, Inc. has a 1-year low of $1.04 and a 1-year high of $8.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 11.01 and a quick ratio of 10.50.

Sight Sciences (NASDAQ:SGHT) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.06. Sight Sciences had a negative return on equity of 45.68% and a negative net margin of 65.90%. The business had revenue of $21.37 million during the quarter, compared to the consensus estimate of $21.32 million. During the same period last year, the firm earned ($0.30) earnings per share. As a group, research analysts anticipate that Sight Sciences, Inc. will post -1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a report on Friday, August 2nd. Morgan Stanley lifted their target price on Sight Sciences from $5.40 to $6.50 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Citigroup boosted their price target on Sight Sciences from $6.00 to $6.50 and gave the stock a “neutral” rating in a research note on Wednesday, July 10th. Finally, Lake Street Capital started coverage on Sight Sciences in a research note on Wednesday, August 21st. They set a “buy” rating and a $10.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $7.25.

Institutional Investors Weigh In On Sight Sciences

A number of institutional investors have recently made changes to their positions in the company. RTW Investments LP acquired a new position in Sight Sciences in the fourth quarter worth $850,000. Jacobs Levy Equity Management Inc. raised its holdings in shares of Sight Sciences by 25.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock worth $1,991,000 after purchasing an additional 76,549 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Sight Sciences by 51.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,653 shares of the company’s stock worth $141,000 after buying an additional 9,106 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Sight Sciences by 5.5% in the 1st quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock valued at $8,218,000 after buying an additional 81,768 shares during the period. Finally, Acadian Asset Management LLC grew its position in shares of Sight Sciences by 256.6% during the 2nd quarter. Acadian Asset Management LLC now owns 83,693 shares of the company’s stock valued at $556,000 after buying an additional 60,220 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.